Trial
NCT03400176
VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Chronic Lymphocytic Leukemia (CLL)
Intervention
VAY736
Why stopped
Business reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-16